We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Partner Therapeutics Begins Phase 2 Inhaled Leukine Trial for COVID-19
Partner Therapeutics Begins Phase 2 Inhaled Leukine Trial for COVID-19
Partner Therapeutics has enrolled the first patient in a phase 2 trial evaluating its inhaled Leukine (sargramostim) for hospitalized COVID-19 patients.